The urologists' perspective in management of lower urinary tract symptoms: the questionnaire-based evidence from nationwide survey in India
DOI:
https://doi.org/10.18203/2320-6012.ijrms20260240Keywords:
Lower urinary tract symptoms, Overactive bladder, Benign prostatic hyperplasia, Urinary tract infections, UrologistsAbstract
Background: Lower urinary tract symptoms (LUTS) encompass storage, voiding, and post-micturition disturbances, commonly associated with conditions such as benign prostatic hyperplasia (BPH), overactive bladder (OAB), and urinary tract infections (UTIs). Despite their high prevalence and significant impact on quality of life (QoL), LUTS are often under-recognized. This survey assesses urologists’ perspectives on the diagnosis and management of LUTS, focusing on real-world practices in the Indian context.
Methods: A cross-sectional survey was conducted among 438 urologists in India from October 2024 to December 2024 to assess clinical practices in managing LUTS. A 20-question questionnaire captured diagnostic preferences, treatment approaches, and clinical perspectives. Responses were compiled and analyzed using Microsoft excel 365, with results presented as counts and percentages and visualized to highlight trends across participants.
Results: In the survey, 80.4% of urologists reported urine culture as the most commonly performed diagnostic test. Age (62.3%) and symptom severity (34.2%) were the main factors guiding treatment decisions. For uncomplicated UTIs, 83.8% preferred Nitrofurantoin. BPH was the most frequent comorbidity with OAB (68.5%), and 53.4% identified lack of patient awareness as a major challenge. For OAB maintenance, 59.4% preferred Mirabegron monotherapy.
Conclusions: The survey provides valuable insights into contemporary prescribing practices in urology. Nitrofurantoin remains the mainstay for uncomplicated UTIs, Mirabegron is increasingly adopted as first-line and maintenance therapy for OAB, and Silodosin, alone or in combination with Dutasteride or Tadalafil, is preferred in BPH, particularly in patients with comorbidities. Limited patient awareness, especially in OAB, highlights the need for improved education and greater integration of individualized, evidence-based pharmacotherapies into routine practice.
Metrics
References
Bharti V, Tiwari RK, Gupta S, Upadhyay R, Singh MK, Singh DK. The spectrum and etiologies of lower urinary tract symptoms in postmenopausal women. Curr Urol. 2023;17(3):179-83. DOI: https://doi.org/10.1097/CU9.0000000000000196
Jyothi, Pavithra K. Lower urinary tract symptoms and its impact on quality of life among adults: A cross-sectional study from a tertiary care hospital, Mangaluru, Karnataka, India. J Clin Diagn Res. 2024;18(11):OC16-20.
Boyle P, Robertson C, Mazzetta C. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int. 2003;92(4):409-14. DOI: https://doi.org/10.1046/j.1464-410X.2003.04369.x
Huang J, Chan CK, Yee S, Deng Y, Bai Y, Chan SC, et al. Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26(2):421-8. DOI: https://doi.org/10.1038/s41391-022-00610-w
Mitsui T, Sekido N, Masumori N, Haga N, Omae K, Saito M, et al. Prevalence and impact on daily life of lower urinary tract symptoms in Japan: Results of the 2023 Japan Community Health Survey (JaCS 2023). Int J Urol. 2024;31(7):747-54. DOI: https://doi.org/10.1111/iju.15454
Wanifuchi A. Prevalence of Discordance Between Patient‐ and Physician‐Reported Questionnaire in Japanese Male: BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(5):S122-8.
Yeboah ED. Prevalence of benign prostatic hyperplasia and prostate cancer in Africans and Africans in the diaspora. J West Afr Coll Surg. 2016;6(4):1-30.
Suresh K. Prostate health in India (BPH and prostate cancer). Arch Cancer Sci Ther. 2022;6(1):009-17. DOI: https://doi.org/10.29328/journal.acst.1001028
Coyne KS, Sexton CC, Kopp ZS, Ebel‐Bitoun C, Milsom I, Chapple C. The impact of overactive bladder on mental health, work productivity and health‐related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011;108(9):1459-71. DOI: https://doi.org/10.1111/j.1464-410X.2010.10013.x
Kamei J, Fujimura T. Urinary tract infection in patients with lower urinary tract dysfunction. J Infect Chemother. 2023;29(8):744-8. DOI: https://doi.org/10.1016/j.jiac.2023.04.019
Abdelmoteleb H, Jefferies ER, Drake MJ. Assessment and management of male lower urinary tract symptoms (LUTS). Int J Surg. 2016;25:164-71. DOI: https://doi.org/10.1016/j.ijsu.2015.11.043
Müller M, Seidenberg R, Schuh SK, Aristomenis KE, Clyde BS, Alexander BL, et al. The development and validation of different decision-making tools to predict urine culture growth out of urine flow cytometry parameter. PLoS One. 2018;13(2):e0193255. DOI: https://doi.org/10.1371/journal.pone.0193255
Neu HC. Optimal characteristics of agents to treat uncomplicated urinary tract infections. Infection. 1992;20(S4):S266-71. DOI: https://doi.org/10.1007/BF01710012
Malde S, Kelly S, Saad S, Sahai A. Case‐finding tools for the diagnosis of OAB in women: A narrative review. Neurourol Urodyn. 2020;39(1):13-24. DOI: https://doi.org/10.1002/nau.24171
Mueller ER, van Maanen R, Chapple C, Paul A, Sender H, Dudley R, et al. Long‐term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study. Neurourol Urodyn. 2019;38(2):779-92. DOI: https://doi.org/10.1002/nau.23919
Shin JH, Choo M. Effectiveness and persistence of mirabegron as a first‐line treatment in patients with overactive bladder in real‐life practice. LUTS: Low Urin Tract Symptoms. 2019;11(3):151-7. DOI: https://doi.org/10.1111/luts.12253
Oh SJ, Cho ST, Kuo HC, Eric Chieh-LC, Yu-Chao H, Kyu-SL, t al. Treatment patterns with mirabegron and antimuscarinics for overactive bladder: A prospective, registry study in Taiwan and South Korea (FAITH). Adv Ther. 2024;41(4):1652-71. DOI: https://doi.org/10.1007/s12325-024-02784-2
Sadasiva Rao G, Sudharani K, Salma Sulthana Sk, Sunita K, Lakshmi Kranthi M. Safety and efficacy of silodosin-dutasteride in the management of benign prostatic hyperplasia. Int J Adv Res. 2022;10(06):601-4. DOI: https://doi.org/10.21474/IJAR01/14927
Manjula S, Krishna KM. Expert opinion on the prescription practices of silodosin and combination therapies in the management of benign prostatic hyperplasia in Indian settings. Int J Urol Res. 2024;6(1):105-10. DOI: https://doi.org/10.33545/26646617.2024.v6.i1b.41
Abdel Razek M, Abolyosr A, Mohammed O, Atef F2, Mohammed T, Ahmed H. Prospective comparative study between silodosin 8 mg versus combination of tadalafil 5 mg and silodosin 4 mg for treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. SVU Int J Med Sci. 2021;0(0):0-0. DOI: https://doi.org/10.21608/svuijm.2021.66651.1116
Abdus Salam M, Nabid Alam M, Rafiqul Islam M, Nazrul Islam M, Faroque Eastiak M. Comparison of safety and efficacy between silodosin monotherapy and silodosin with tadalafil add-on therapy in patients with benign prostatic hyperplasia. Front Health Inform. 2024;13(8):2901-6.
Malde S, Umbach R, Wheeler JR. A systematic review of patients’ values, preferences, and expectations for the diagnosis and treatment of male lower urinary tract symptoms. Eur Urol. 2021;79(6):796-809. DOI: https://doi.org/10.1016/j.eururo.2020.12.019
Corcos J, Przydacz M, Campeau L. CUA guideline on adult overactive bladder. Can Urol Assoc J. 2017;11(5):E142-73. DOI: https://doi.org/10.5489/cuaj.4586
Reddy J, Arul SKA, Vinodhini VM, Prasath N, Mansi R. Association of Vitamin D and Prostate Health Status in Men: An Analytical Cross-Sectional Study. Cureus. 2024;16(12):e74959. DOI: https://doi.org/10.7759/cureus.74959
Thompson IM, Goodman PJ, Tangen CM, Howard LP, Lori MM, Paul AG, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013;369(7):603-10. DOI: https://doi.org/10.1056/NEJMoa1215932
Wang L, Lei Y, Gao Y, Dong C, Qisheng T, Ruixiao L, et al. Association of finasteride with prostate cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99(15):e19486. DOI: https://doi.org/10.1097/MD.0000000000019486
Downloads
Published
How to Cite
Issue
Section
